Amgen Inc. $AMGN Shares Sold by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 18.0% during the third quarter, HoldingsChannel reports. The firm owned 6,995 shares of the medical research company’s stock after selling 1,535 shares during the period. Geneos Wealth Management Inc.’s holdings in Amgen were worth $1,974,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Hennion & Walsh Asset Management Inc. raised its position in Amgen by 12.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 7,746 shares of the medical research company’s stock worth $2,186,000 after buying an additional 859 shares during the last quarter. Arcataur Capital Management LLC grew its holdings in shares of Amgen by 4.3% in the 3rd quarter. Arcataur Capital Management LLC now owns 1,762 shares of the medical research company’s stock worth $497,000 after acquiring an additional 73 shares during the period. Forza Wealth Management LLC increased its position in shares of Amgen by 5.4% in the third quarter. Forza Wealth Management LLC now owns 6,717 shares of the medical research company’s stock valued at $1,896,000 after buying an additional 347 shares in the last quarter. Gries Financial LLC purchased a new position in Amgen during the 3rd quarter valued at about $287,000. Finally, Torray Investment Partners LLC raised its position in Amgen by 3.8% during the third quarter. Torray Investment Partners LLC now owns 72,530 shares of the medical research company’s stock worth $20,468,000 after acquiring an additional 2,672 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Acquisition strengthens oncology pipeline — Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million, adding a differentiated preclinical AML degrader and expanding its early‑stage oncology discovery capabilities; this is seen as a strategic bolt‑on to Amgen’s cancer portfolio. Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
• Positive Sentiment: Pipeline progress in obesity — Amgen advanced an early‑stage obesity candidate with a new injection delivery trial, broadening its non‑oncology growth prospects and showing R&D diversification that appeals to long‑term investors. Amgen Advances Early-Stage Obesity Candidate With New Injection Trial
• Neutral Sentiment: Management to present at JPM — Amgen will present at the 44th J.P. Morgan Healthcare Conference; investors will watch for management commentary or guidance updates that could act as a catalyst but this is routine investor outreach. AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
• Neutral Sentiment: Longer‑term product / patent dynamics discussed — Coverage noting how new drug launches and patent risks could reshape Amgen’s growth outlook; useful context for valuation but not an immediate news shock. How New Drug Launches And Patent Risks Are Rewriting The Story For Amgen (AMGN)
• Negative Sentiment: Near‑term earnings pressure expected — previews ahead of Q4 2025 suggest analysts are braced for a low double‑digit profit decline, which could cap near‑term upside and increase sensitivity to upcoming results. What to Expect From Amgen’s Q4 2025 Earnings Report
• Negative Sentiment: License deal implies milestone spend — a report indicates Disco Pharma is set to earn up to $618 million from an Amgen license agreement, signaling a meaningful cash/milestone commitment by Amgen that could weigh on near‑term free cash flow (though it also acquires rights to potentially valuable assets). Disco Pharma set to earn $618M from Amgen license deal

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. Insiders own 0.76% of the company’s stock.

Amgen Trading Up 3.5%

Shares of Amgen stock opened at $341.64 on Thursday. Amgen Inc. has a fifty-two week low of $259.82 and a fifty-two week high of $346.38. The business’s fifty day moving average is $328.43 and its two-hundred day moving average is $303.75. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The firm has a market cap of $183.97 billion, a PE ratio of 26.40, a P/E/G ratio of 3.01 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same period in the prior year, the firm posted $5.58 earnings per share. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a $2.52 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio is 73.57%.

Analyst Ratings Changes

AMGN has been the subject of a number of recent research reports. Truist Financial assumed coverage on shares of Amgen in a research note on Monday, November 24th. They set a “hold” rating and a $318.00 price objective for the company. Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. HSBC restated a “buy” rating and issued a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Finally, Citigroup increased their price objective on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research note on Wednesday, September 24th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average target price of $338.50.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.